Last Updated: June 29, 2026

RILPIVIRINE Drug Patent Profile

Name: RILPIVIRINE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Rilpivirine, and what generic alternatives are available?

Rilpivirine is a drug marketed by Somerset Theraps Llc and is included in one NDA.

The generic ingredient in RILPIVIRINE is rilpivirine hydrochloride. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the rilpivirine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rilpivirine

A generic version of RILPIVIRINE was approved as rilpivirine hydrochloride by SOMERSET THERAPS LLC on January 29^th, 2026.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for RILPIVIRINE?
What are the global sales for RILPIVIRINE?
What is Average Wholesale Price for RILPIVIRINE?

Summary for RILPIVIRINE

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	RILPIVIRINE at DailyMed

Drug patent expirations by year for RILPIVIRINE

Pharmacology for RILPIVIRINE

Drug Class	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Non-Nucleoside Reverse Transcriptase Inhibitors

US Patents and Regulatory Information for RILPIVIRINE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Somerset Theraps Llc	RILPIVIRINE HYDROCHLORIDE	rilpivirine hydrochloride	TABLET;ORAL	218798-001	Jan 29, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DrugChatter Q&A for RILPIVIRINE

Rilpivirine edurant fda approval date?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.